Michael A Curran

List of Publications by Year in Descending Order

49 papers	3,873 citations	24 h-index	54 g-index
54 ext. papers	4,879 ext. citations	9.8 avg, IF	5.5 L-index

#	Paper	IF	Citations
49	Method of long-term, recurrent, intracerebroventricular infusion of cellular therapy in mice.. *Journal of Neuroscience Methods*, **2022**, 371, 109529	3	
48	ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer. *Science Immunology*, **2022**, 7,	28	2
47	A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies. *Clinical Cancer Research*, **2021**, 27, 3050-3060	12.9	7
46	Development of Immunotherapy Combination Strategies in Cancer. *Cancer Discovery*, **2021**, 11, 1368-1397	24.4	27
45	Opening of the Blood-Brain Barrier Using Low-Intensity Pulsed Ultrasound Enhances Responses to Immunotherapy in Preclinical Glioma Models. *Clinical Cancer Research*, **2021**, 27, 4325-4337	12.9	12
44	LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade. *Science Translational Medicine*, **2021**, 13,	17.5	14
43	Intratumoral Delivery of STING Agonist Results in Clinical Responses in Canine Glioblastoma. *Clinical Cancer Research*, **2021**, 27, 5528-5535	12.9	2
42	High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege **2021**, 9,		7
41	Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma. *Journal of Hepatocellular Carcinoma*, **2021**, 8, 1195-1207	5.3	6
40	MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma. *OncoImmunology*, **2020**, 9, 1846915	7.2	12
39	Tumor hypermetabolism confers resistance to immunotherapy. *Seminars in Cancer Biology*, **2020**, 65, 155-163	12.7	7
38	mRNA Display Discovery of a Novel Programmed Death Ligand 1 (PD-L1) Binding Peptide (a Peptide Ligand for PD-L1). *ACS Chemical Biology*, **2020**, 15, 1630-1641	4.9	5
37	Immune biology of glioma-associated macrophages and microglia: functional and therapeutic implications. *Neuro-Oncology*, **2020**, 22, 180-194	1	37
36	Profiling of patients with glioma reveals the dominant immunosuppressive axis is refractory to immune function restoration. *JCI Insight*, **2020**, 5,	9.9	16
35	Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype. *Cancer Immunology Research*, **2020**, 8, 1365-1380	12.5	13
34	Discovery of IACS-8803 and IACS-8779, potent agonists of stimulator of interferon genes (STING) with robust systemic antitumor efficacy. *Bioorganic and Medicinal Chemistry Letters*, **2019**, 29, 126640	2.9	15
33	Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV oral cancer **2019**, 7, 252		25

32	Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. *Nature Immunology*, **2019**, 20, 835-851	19.1	147
31	TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma **2019**, 7, 323		29
30	EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy **2019**, 7, 5		4
29	New Hope for Therapeutic Cancer Vaccines in the Era of Immune Checkpoint Modulation. *Annual Review of Medicine*, **2019**, 70, 409-424	17.4	30
28	PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8 T-Cell-Driven Antitumor Immunity. *Clinical Cancer Research*, **2018**, 24, 2383-2394	12.9	50
27	Preclinical Data Supporting Antitumor Activity of PD-1 Blockade. *Cancer Journal (Sudbury, Mass.)*, **2018**, 24, 2-6	2.2	3
26	Activation of 4-1BB on Liver Myeloid Cells Triggers Hepatitis via an Interleukin-27-Dependent Pathway. *Clinical Cancer Research*, **2018**, 24, 1138-1151	12.9	36
25	Mucosal HPV E6/E7 Peptide Vaccination in Combination with Immune Checkpoint Modulation Induces Regression of HPV Oral Cancers. *Cancer Research*, **2018**, 78, 5327-5339	10.1	15
24	Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma. *JCI Insight*, **2018**, 3,	9.9	31
23	Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy. *Journal of Clinical Investigation*, **2018**, 128, 5137-5149	15.9	159
22	Suppression of stromal-derived Dickkopf-3 (DKK3) inhibits tumor progression and prolongs survival in pancreatic ductal adenocarcinoma. *Science Translational Medicine*, **2018**, 10,	17.5	14
21	Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain. *Nature Communications*, **2017**, 8, 1447	17.4	48
20	Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity. *Cancer Immunology Research*, **2017**, 5, 676-684	12.5	91
19	Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. *Clinical Cancer Research*, **2017**, 23, 1388-1396	12.9	199
18	Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. *JCI Insight*, **2016**, 1,	9.9	226
17	Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, E5290-9	11.5	59
16	4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity. *Frontiers in Oncology*, **2015**, 5, 117	5.3	153
15	Immune checkpoint combinations from mouse to man. *Cancer Immunology, Immunotherapy*, **2015**, 64, 885-92	7.4	33

14	Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin. *Journal of Experimental Medicine*, **2013**, 210, 743-55	16.6	111
13	Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab.. *Journal of Clinical Oncology*, **2013**, 31, 3003-3003	2.2	21
12	Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-B signaling improves the efficacy of immunotherapy in a brain cancer model. *Neurotherapeutics*, **2012**, 9, 827-43	6.4	29
11	Response to "Ipilimumab (Yervoy) and the TGN1412 catastrophe". *Immunobiology*, **2012**, 217, 590-2	3.4	9
10	Repertoire enhancement with adoptively transferred female lymphocytes controls the growth of pre-implanted murine prostate cancer. *PLoS ONE*, **2012**, 7, e35222	3.7	4
9	Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. *PLoS ONE*, **2011**, 6, e19499	3.7	168
8	PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 4275-80	11.5	1276
7	Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors. *Cancer Research*, **2009**, 69, 7747-55	10.1	101
6	Protection of human pancreatic islets using a lentiviral vector expressing two genes: cFLIP and GFP. *Cell Transplantation*, **2008**, 17, 793-802	4	7
5	CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. *Journal of Clinical Investigation*, **2006**, 116, 1935-45	15.9	531
4	Prolonged transgene expression in murine salivary glands following non-primate lentiviral vector transduction. *Molecular Therapy*, **2005**, 12, 137-43	11.7	14
3	Retrovirally transferred genes inhibit apoptosis in an insulin-secreting cell line: implications for islet transplantation. *Cell Transplantation*, **2004**, 13, 489-96	4	9
2	Prolonged liver-specific transgene expression by a non-primate lentiviral vector. *Biochemical and Biophysical Research Communications*, **2004**, 320, 998-1006	3.4	32
1	Efficient transduction of pancreatic islets by feline immunodeficiency virus vectors1. *Transplantation*, **2002**, 74, 299-306	1.8	23